Introduction
============

Angioimmunoblastic T-cell lymphoma (AITL) is a T-cell lymphoma composed of clusters of atypical medium-sized or large neoplastic lymphocytes with clear-to-pale cytoplasm and the infiltration of reactive lymphocytes, eosinophils, plasma cells, histiocytes and follicular dendritic cells ([@B1]).

During T-cell maturation, naïve T cells comprise two distinct cell types: CD4-positive and CD8-negative helper T cells (Th), and CD4-negative and CD8-positive cytotoxic T cells. Following antigen stimulation, naïve Th cells differentiate into several subtypes of effector Th cells: Th type 1 (Th1), Th type 2 (Th2), follicular helper T cells (TFH), regulatory T cells (Treg), interleukin-17-producing T cells (Th17), central memory T cells, and effector memory T cells ([@B2]).

Previously, these subtypes of effector Th cells were classified according to their pattern of cytokine secretion and expression of surface antigens, including chemokine receptors. Recent immunologic studies, however, have identified several transcription factors responsible for T-cell differentiation. The master regulators associated with T-cell, Th, Th1, Th2, TFH, Treg, and Th17 differentiation are reportedly BCL11B ([@B3], [@B4]), Th-POK ([@B5]), T-Bet ([@B6]), GATA3 ([@B7]), BCL6 ([@B8], [@B9]), FOXP3 ([@B10]), and RORγt ([@B11]), respectively.

The detection of the expression of these master regulators has contributed to the identification of the normal counterparts of some histological subtypes of T-cell lymphoma. For example, the normal counterpart of some adult T-cell leukemia patients was reported to be Treg because of the detection of FOXP3 expression ([@B12]). In addition, we previously reported the postulated that the normal counterparts of 10 peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) patients were Th1 (T-BET-positive), Th2 (GATA3-positive), TCM (CCR7- and CD62L-positive), and TFH (BCL6-positive) ([@B13]).

The neoplastic cells of AITL are thought to originate from effector Th cells because these tumor cells express surface antigens such as pan-T-cell (CD3), effector-T-cell (CD45RO) ([@B14]), and Th (CD4) markers. Regarding the subtypes of effector Th cells, several immunohistochemical studies ([@B15]-[@B18]) have shown that the neoplastic cells of AITL express the transcriptional factors and surface antigens associated with TFH, such as BCL6, CXCL13, PD-1, and SAP. A gene expression profile analysis also demonstrated a molecular link between AITL and TFH cells ([@B19], [@B20]). These results indicate that the neoplastic cells of AITL are derived from TFH cells.

In this study, to identify the postulated normal counterpart of AITL with respect to the master regulators of T-cell differentiation, we immunohistochemically analyzed the expression of BCL11B, Th-POK, and BCL6. Furthermore, we compared the results with those for previously known markers of these cells in AITL patients.

Materials and Methods
=====================

Patients
--------

The study population comprised 15 Japanese patients with histopathologically diagnosed AITL at the hospital of Kyoto Prefectural University of Medicine and Kyoto Minami Hospital between 1990 and 2012. These patients were 4 men and 11 women who ranged in age from 38 to 85 years ([Table 1](#t001){ref-type="table"}, [Figure A](#g001){ref-type="fig"}). The clinical data of patients No. 1-4, 6, and 9-15 were previously reported ([@B21]). Ten patients (No. 2, 4, 6, 8-13, 15) were treated with cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) regimen as first-line therapy. Two patients received stem cell transplantation. Autologous and reduced-intensity allogeneic peripheral blood stem cell transplantations (PBSCTs) were performed in Patient 4, and autologous PBSCT and myeloablative cord blood transplantation were performed in Patient 9.

###### 

Findings of Biopsied Samples and Epstein-Barr Viral Infection of the 15 Patients with Angioimmunoblastic T-cell Lymphoma.

  Patient   Age/ Sex   Biopsy location       *TCR* C*β*1 rearrangement   Representative karyotype                                                                                                               EBER-ISH
  --------- ---------- --------------------- --------------------------- -------------------------------------------------------------------------------------------------------------------------------------- ----------
  1         61/M       Lymph node            ND                          46,XY                                                                                                                                  \+
  2         68/F       Lymph node            *TCR* J*β* -                t(1;14)(q21;q32.3) \[3/21\]                                                                                                            \+
  3         65/F       Lymph node            \+                          46,XX                                                                                                                                  \-
  4         57/F       Subcutaneous nodule   \+                          47,XX,+3 \[6/8\] 48,idem,+?21\[1/8\]                                                                                                   \-
  5         85/F       Lymph node            ND                          46,XX                                                                                                                                  \-
  6         68/F       Skin/Lymph node       \- (PB)                     46,XX,del(9)(q?),add(14)(q32) \[1/20\]                                                                                                 \-
  7         81/F       Lymph node            ND                          46,XX                                                                                                                                  \+
  8         70/M       Lymph node            NE                          47,XY,add(4)(q21),del(5)(q?),+add(6)(p11), del13(q?),add(15)(p11),add(19)(q13) \[2/20\]                                                \+
  9         38/M       Lymph node            ND                          46,XY,add(1)(p11),add(4)(p11),add(8)(q24), del(9)(q?),11,add(14)(q32),15,add(18)(q21), add(19)(p13),add(21)(q22),-22,-22,+4mar \[2\]   \-
  10        68/M       Lymph node            \+                          No metaphase                                                                                                                           \-
  11        64/F       Lymph node            ND                          47,XX,add(1)(q21),del(2)(q?),+der(7)(1;7)(q12;q32),add(10)(p11.2), add(13)(p11.2) \[1/15\]                                             \-
  12        75/F       Lymph node            ND                          46,XX                                                                                                                                  \-
  13        63/F       Skin                  ND                          ND                                                                                                                                     \-
  14        83/F       Lymph node            ND                          46,XX,inv(9)(p24q21) \[1/20\]                                                                                                          \-
  15        68/F       Lymph node            ND                          No metaphase                                                                                                                           \-

ND: no data, NE: not evaluable, PB: peripheral blood, EBER-ISH: Epstein-Barr virus-encoded RNA *insitu* hybridization

![Typical results of the immunohistochemical analysis. All of the antigens except for CD45RA and CD8 were positive. A: Hematoxylin and Eosin staining, B: BCL11B, C: CD3, D: CD45RA, E: CD45RO, F: Th-POK, G: CD4, H: CD8, I: BCL6, J: CXCL13, K: PD-1, L: SAP. A-C: Patient 15, D-H: Patient 14, I-L: Patient 2](1349-7235-56-2851-g001){#g001}

Informed consent was obtained from each patient in accordance with institutional guidelines. Each patient enrolled in the study was reviewed by two pathologists for confirmation of AITL. The histopathologic diagnosis was in accordance with the World Health Organization Classification of Neoplastic Disorders of the Lymphoid Tissues ([@B1]).

Methods
-------

We subjected 4-μm-thick paraffin-embedded sections of diagnostic lymph node or skin biopsy specimens to immunohistochemical staining using a standard indirect avidin-biotin horseradish peroxidase method and diaminobenzidine (DAB) color development (DAKO Envision™, Carpinteria, and Cell & Tissue Staining Kit; R&D Systems, Minneapolis, USA). In line with previously reported studies, the patients were considered positive if ≥20% of the tumor cells were stained with an antibody ([@B16], [@B17]). Paraffin-embedded lymph nodes with a histological diagnosis of nonspecific lymphadenitis and diffuse large B-cell lymphoma were used as negative and positive staining controls.

Primary antibodies against the following transcription factors were introduced: BCL11B (dilution 1: 100; Novus Biologicals, Littleton, USA), Th-POK (dilution 1:50; Abgent, San Diego, USA), and BCL6 (PG-B6p, dilution 1: 15; DAKO). Primary antibodies against the following surface antigens and chemokine were used: CD3 in clinical use, CD4 (4B12, dilution 1:70; DAKO), CD8 (C8/144B, no dilution; DAKO), CD45RA (4KB5, dilution 1: 70; DAKO), CD45RO (UCHL-1, dilution 1:70; DAKO), CXCL13 (dilution 15 mg/mL; R&D Systems), PD-1 (dilution 15 μg/mL; R&D Systems) and SAP (SH2D1A, dilution 1: 250; Santa Cruz Biotechnology, Santa Cruz, USA). All antibodies were treated and used in accordance with the manufacturers\' instructions.

We analyzed the relationship between the expression of the master regulators and the immunohistochemical and clinical features listed in [Tables 2](#t002){ref-type="table"} and [3](#t003){ref-type="table"} using Fisher\'s exact test. The overall survival (OS) distributions were calculated with the Kaplan-Meier method and compared by the log-rank test.

###### 

Clinical Characteristics of the 15 Patients with Angioimmunoblastic T-cell Lymphoma.

  Patient   LDH (IU/L)   Ann Arbor Stage   PS    Extranodal sites                WBC (×10^4^/μL)   Hb (g/dL)   Platelet count (×10^4^/μL)   IgA(mg/dL)   PIAI   ATPI      Survival (months)
  --------- ------------ ----------------- ----- ------------------------------- ----------------- ----------- ---------------------------- ------------ ------ --------- -------------------
  1         1682H        IVB               0     Pleural effusion Ascites        35,200            5.5         28.4                         ND           H      H         179
  2         191          IIISB             0     \-                              9,400             9.9         35.8                         528          H      HI        37
  3         556H         IIISA             0     \-                              7,100             11.3        13.2                         373          H      L         145+
  4         226          IIISB             0     Skin                            9,000             9.7         4.2                          168          H      L         74+
  5         264H         IVA               0     Pleural effusion Hepatomegary   7,100             6.6         1.8                          ND           H      HI or H   9+
  6         315H         IVA               0     Skin                            7,500             12.9        30.2                         348          L      L         78+
  7         242H         ND                0     ND                              6,600             10.2        14.7                         1,292        H      HI        ND
  8         193          IIIA              0     \-                              4,900             14.0        18.5                         554          L      LI        110+
  9         198          IVB               0-1   \-                              4,300             14.9        25.5                         111          L      L         72+
  10        238          IIISA             0     Pancreas                        7,600             11.5        17.5                         1,378        L      HI        93+
  11        993H         IVB               1     Hepatomegary                    8,700             11.2        0.3                          410          H      LI        4
  12        477H         IVB               4     Bone marrow                     19,300            8.4         4.3                          950          H      H         62+
  13        277H         IVB               0     Skin                            7,280             10.5        27.3                         423          H      HI        45
  14        276H         IA                0     \-                              8,200             14.9        15.9                         367          L      L         33+
  15        279H         IVB               0     Ileum                           6,300             11.1        17.1                         70           H      L         52

PIAI: Prognostic Index for AITL (34), ATPI: AITL prognostic index (35), L: low-risk, LI: low-intermediate-risk, HI: high-intermediate risk, H: high risk, ND: no data

###### 

Results of the Immunohistochemical Analysis.

                      T-cell         Effector T-cell        Th       TFH                               
  ------------------- -------- ----- ----------------- ---- ----- -- ----- ---- ---- -- ---- ---- ---- -----
  1                   \+       \+                      \+   \+       \+    \+   \-      \+   \+   \+   \+
  2                   \-       \+                      \-   \+       \+    \+   \-      \+   \+   \+   \+
  3                   \+       \+                      \+   \+       \+    \+   \+      \+   \-   \+   \+
  4                   \+       \+                      \-   \+       \+    \+   \+      \+   \+   \+   \+
  5                   \+       \+                      \-   \+       \-    \+   \+      \+   \+   \+   \+
  6                   \+       \+                      \-   \+       \-    \+   \-      \+   \-   \+   \+
  7                   \+       \+                      \-   \+       \-    \+   \-      \+   \-   \+   \+
  8                   \-       \+                      \-   \+       \-    \+   \-      \+   \+   \+   \+
  9                   \-       \+                      \-   \+       \-    \-   \-      \+   \+   \+   \+
  10                  \-       \+                      \-   \+       \-    \+   \-      \+   \-   \-   \+
  11                  \-       \+                      \-   \+       \+    \-   \-      \-   \+   \+   \+
  12                  \+       \+                      \-   \+       \+    \+   \+      \-   \-   \+   \+
  13                  \+       \+                      \-   \+       \+    \+   \+      \+   \-   \+   \+
  14                  \+       \+                      \-   \+       \+    \+   \-      \-   \-   \+   \+
  15                  \+       \+                      \-   \+       \+    \-   \+      \-   \+   \+   \+
  positive rate (%)   67       100                     13   100      60    80   40      73   53   93   100

Results
=======

The immunohistochemical results are shown in [Table 3](#t003){ref-type="table"}. We first analyzed the expression of the master regulator (BCL11B) and the surface marker (CD3) of T-cells ([Figure B, C](#g001){ref-type="fig"}). BCL11B was detected in 10 patients, and CD3 was detected in all AITL patients. We then analyzed the expression of the master regulator of Th (Th-POK) and the surface markers (CD4 and CD8), naïve T-cell antigen (CD45RA), and effector T-cell antigen (CD45RO) ([Figure D-H](#g001){ref-type="fig"}). Th-POK was detected in 9 patients, while 7 patients showed the phenotype of the surface antigens of Th, i.e. CD4-positive and CD8-negative. All patients were positive for the effector T-cell marker (CD45RO), and all patients except two were negative for the naïve T-cell marker (CD45RA) ([@B14]). Regarding the expression of the master regulator (BCL6) and the surface antigens of TFH (CXCL13, PD-1 and SAP), BCL6, CXCL13, PD-1, and SAP were detected in 11, 8, 14, and all patients, respectively ([Figure I-L](#g001){ref-type="fig"}).

Regarding the associations between the expression of these master regulators of T-cell differentiation and the clinical characteristics shown in [Table 2](#t002){ref-type="table"}, the elevation of serum lactate dehydrogenase (LDH) beyond the normal upper limit was significantly associated with the BCL11B expression (p=0.0170). The patients in this study were divided into three groups based on the expression of Th-POK and BCL6, consisting of double-positive (n=5), Th-POK single-positive (n=4), and BCL6 single-positive patients (n=6). Th-POK single-positive patients showed a significantly shorter OS than the other 2 groups (median OS: 33.0 months vs. 74.0 months, p=0.020). Five of six BCL6 single-positive patients showed negativity of CD8, although this result was not statistically significant (p=0.42).

Discussion
==========

We detected the master regulators of T (BCL11B), Th (Th-POK), and TFH (BCL6) cells in 10 (67%), 9 (60%), and 11 (73%) of the 15 AITL patients, respectively. Many functions of BCL11B have been reported. Physiologically, BCL11B plays critical roles in the differentiation ([@B3], [@B4]) and survival ([@B22]) of the T-cell lineage identity. In oncogenesis, several contradictory functions of BCL11B have been reported, such as haploinsufficient tumor suppressor effects ([@B23]) and anti-apoptosis effects ([@B24]). There have also been conflicting findings concerning the expression of *BCL11B* in T-cell lymphoma/leukemia. While monoallelic *BCL11B* deletions or missense mutations are reportedly found in 9% of T-cell acute lymphoblastic leukemia (T-ALL) ([@B23]), *BCL11B* mRNA expression has been reported in 36% (8/22) of T-ALL cell lines ([@B25]) and acute type adult T-cell leukemia/lymphoma ([@B26]). However, to our knowledge, there have been no previous reports concerning the BCL11B expression in AITL patients.

Th-POK and BCL6 are master regulators of Th and TFH lineage commitment, respectively ([@B5], [@B8], [@B9]), both of which belong to the poxvirus and zinc finger (POZ) and Krüppel-type (POK) protein family. POK family members often act as oncogenes in various hematological malignancies ([@B27]). For example, chromosomal translocation involving *PLZF* \[t(11 ; 17) (q23 ; q21), *PLZF*/*RARα* and *RARα*/*PLZF*\] is associated with acute promyelocytic leukemia ([@B28]). *LRF* acts as a proto-oncogene and is highly expressed in non-Hodgkin's lymphoma ([@B29]). Furthermore, the dysregulation of *Th-POK* ([@B30]) and *BCL6* ([@B31]) causes non-Hodgkin's T- and B-cell lymphoma, respectively. Very few reports have examined the expression of Th-POK in lymphoma, including AITL. We previously reported that Th-POK was immunohistochemically expressed in 10 of 10 PTCL, NOS patients ([@B13]). Although Th-POK is a master regulator of CD4-positive/CD8-negative Th lineage commitment ([@B5]), our analysis showed that most (5/6) Th-POK-negative patients were also CD4-positive/CD8-negative. However, previous reports have examined the expression of BCL6 in AITL. Yuan et al. reported that extrafollicular BCL6 expression was observed in all 8 AITL patients they analyzed, with values ranging from 10% to 50% ([@B32]), and Dupuis et al. reported BCL6 expression in 16 of 21 (76%) AITL patients ([@B16]). Recently, a loss-of-function mutation in *TET2* was reported to be frequent (33-83%) in AITL patients, resulting in the deregulated BCL6 expression caused by hypermethylation at intron 1 of *BCL6* ([@B33]).

While CD3, a T-cell marker, was positive for all patients in our study, only 47% (7/15) of the patients featured a set of surface antigens compatible with Th (CD4-positive and CD8-negative). As for TFH markers, CXCL13, PD-1, and SAP were positive for 53% (8/15), 93% (14/15), and all (15/15) patients in our study, respectively, the corresponding values reported by other studies were 86% (25/29) ([@B15]), 100% (29/29) ([@B16]), 86% (42/49) ([@B18]), 100% (23/23) ([@B17]), and 86% (59/69) ([@B18]), respectively. The presence of a polymorphous infiltrate with reactive inflammatory cells often makes the histological diagnosis of AITL difficult. However, the detection of master regulators of T-cell differentiation in T-cell lymphomas is essential for determining their normal counterparts. An immunohistochemical analysis combining these conventional surface markers and the master regulators of T-cell differentiation may therefore improve the accuracy of the histological diagnosis of AITL.

Because BCL11B, Th-POK and BCL6 play roles not only as master regulators of T-cell differentiation but also in oncogenesis, as described above, the expression of these regulators might be associated with the pathogenesis and clinical findings of AITL. In the present study, the BCL11B expression was significantly associated with the elevation of the serum LDH level beyond its normal upper limit, and Th-POK-positive/BCL6-negative patients showed a worse OS than other patients. Two recent reports regarding the prognosis of AITL were published by the International Peripheral T-cell Project (Prognostic Index for AITL, PIAI) ([@B34]) and Japan (AITL Prognostic Index, ATPI) ([@B35]). We analyzed only a limited number of patients in the present study. Further investigations including the findings of these master regulators are needed to clarify the clinical characteristics associated with the pathophysiology of T-cell lymphoma.
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